Room 302, No. 88 building, #887 Zuchongzhi road, Zhangjiang Hi-tech Park, Pudong, Shanghai
InCibitorTM is a complement inhibitor platform developed by Longbio independently. The bi-functional complement inhibitor LP-005 developed based on this platform is going to start Phase II/III study in 2024. At the same time, Longbio is exploring the development of drugs related to hematology, nephrology, neurology, ophthalmology, oncology, and gene therapy based on this platform.
High complement inhibition, both in AP (alternative pathway), CP (classical pathway) and LP (lectin pathway)
~20Kd，excellent tissue penetration
Great drug properties with optimized solubility
Good performance on PK/PD
Paroxysmal nocturnal hemoglobinuria(PNH)
Generalized mvasthenia gravis (gMG)
Myelin-associated glycoprotein associated neuropathies (MAG-PN)
amyotrophic lateral sclerosis (ALS)
IgA nephropathy (lgAN)
Lupus nephropathy(LN)
C3 glomerulopathy (C3G)
DryAMD
AAV-based (new sequence
Oncolytic virus
Combined with I/0
